@article{d58d1464895f41828e410a899f91665e,
title = "High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome.",
abstract = "Introduction: This study describes the characteristics of the metabolic syndrome in HIV-positive patients in the Data Collection on Adverse Events of Anti-HIV Drugs study and discusses the impact of different methodological approaches on estimates of the prevalence of metabolic syndrome over time. Methods: We described the prevalence of the metabolic syndrome in patients under follow-up at the end of six calendar periods from 2000 to 2007. The definition that was used for the metabolic syndrome was modified to take account of the use of lipid-lowering and antihypertensive medication, measurement variability and missing values, and assessed the impact of these modifications on the estimated prevalence. Results: For all definitions considered, there was an increasing prevalence of the metabolic syndrome over time, although the prevalence estimates themselves varied widely. Using our primary definition, we found an increase in prevalence from 19.4% in 2000/2001 to 41.6% in 2006/2007. Modification of the definition to incorporate antihypertensive and lipid-lowering medication had relatively little impact on the prevalence estimates, as did modification to allow for missing data. In contrast, modification to allow the metabolic syndrome to be reversible and to allow for measurement variability lowered prevalence estimates substantially. Discussion: The prevalence of the metabolic syndrome in cohort studies is largely based on the use of nonstandardized measurements as they are captured in daily clinical care. As a result, bias is easily introduced, particularly when measurements are both highly variable and may be missing. We suggest that the prevalence of the metabolic syndrome in cohort studies should be based on two consecutive measurements of the laboratory components in the syndrome definition. {\textcopyright} 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.",
keywords = "Epidemiology, HIV, Metabolic syndrome, Observational study, antihypertensive agent, antilipemic agent, adult, article, controlled study, female, follow up, human, Human immunodeficiency virus infected patient, major clinical study, male, metabolic syndrome X, prevalence, priority journal, Adult, Antihypertensive Agents, CD4 Lymphocyte Count, Cohort Studies, Female, HIV Infections, HIV-1, Humans, Hypolipidemic Agents, Male, Metabolic Syndrome X, Middle Aged, Prevalence, Prospective Studies, United States",
author = "S.W. Worm and N. Friis-M{\o}ller and M. Bruyand and A.D. Monforte and M. Rickenbach and P. Reiss and W. El-Sadr and A. Phillips and J. Lundgren and C. Sabin and Ferran Torres",
note = "Cited By :71 Export Date: 17 February 2022 CODEN: AIDSE Correspondence Address: Worm, S. W.; Copenhagen HIV Programme (CHIP), , Copenhagen, Denmark; email: sww@cphiv.dk Chemicals/CAS: Antihypertensive Agents; Hypolipidemic Agents References: Executive summary of the third report of the national cholesterol educational program (NCEP) expert panel on detection, evaluation and treatment of high cholesterol in adults (Adult treatment III) (2005) JAMA, 285, pp. 2486-2497. , Expert panel on detection EaToHBCiA; Fontas, E., Van, L.F., Sabin, C.A., Friis-Moller, N., Rickenbach, M., D'Arminio, M.A., Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? (2004) J Infect Dis, 189, pp. 1056-1074; Riddler, S.A., Smit, E., Cole, S.R., Li, R., Chmiel, J.S., Dobs, A., Impact of HIV infection and HAART on serum lipids in men (2003) JAMA, 289, pp. 2978-2982; Young, J., Weber, R., Rickenbach, M., Furrer, H., Bernasconi, E., Hirschel, B., Tarr, P.E., Bucher, H.C., Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV Cohort Study (2005) Antiviral Therapy, 10 (5), pp. 585-591; Jacobson, D.L., Tang, A.M., Spiegelman, D., Thomas, A.M., Skinner, S., Gorbach, S.L., Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey) (2006) J Acquir Immune Defic Syndr, 43, pp. 458-466; Samaras, K., Wand, H., Matthew, L., Emery, S., Cooper, D., Carr, A., Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: Associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia (2007) Diabetes Care, 30 (1), pp. 113-119. , http://care.diabetesjournals.org/cgi/reprint/30/1/113, DOI 10.2337/dc06-1075; Bergersen, B.M., Schumacher, A., Sandvik, L., Bruun, J.N., Birkeland, K., Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controls (2006) Scand J Infect Dis, 38, pp. 682-689; Sobieszczyk, M.E., Hoover, D.R., Anastos, K., Mulligan, K., Tan, T., Shi, Q., Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study (2008) J Acquir Immune Defic Syndr, 48, pp. 272-280; Grinspoon, S.K., Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus (2005) Am J Med, 118 (SUPPL. 2), pp. 23S-28S; Jerico, C., Knobel, H., Montero, M., Ordonez-Llanos, J., Guelar, A., Gimeno, J.L., Metabolic syndrome among HIV-infected patients: Prevalence, characteristics, and related factors (2005) Diabetes Care, 28, pp. 132-137; Bonfanti, P., Giannattasio, C., Ricci, E., Facchetti, R., Rosella, E., Franzetti, M., HIV and metabolic syndrome: A comparison with the general population (2007) J Acquir Immune Defic Syndr, 45, pp. 426-431; Mondy, K., Overton, E.T., Grubb, J., Tong, S., Seyfried, W., Powderly, W., Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population (2007) Clin Infect Dis, 44, pp. 726-734; Adeyemi, O., Rezai, K., Bahk, M., Badri, S., Thomas-Gossain, N., Metabolic syndrome in older HIV-infected patients: Data from the CORE50 cohort (2008) AIDS Patient Care STDS, 22, pp. 941-945; Friis-Moller, N., Sabin, C.A., Weber, R., D'Arminio, M.A., El-Sadr, W.M., Reiss, P., Combination antiretroviral therapy and the risk of myocardial infarction (2003) N Engl J Med, 349, pp. 1993-2003; Friis-Moller, N., Weber, R., Reiss, P., Thiebaut, R., Kirk, O., D'Arminio, M.A., Cardiovascular disease risk factors in HIV patients: Association with antiretroviral therapy. Results from the DAD study (2003) AIDS, 17, pp. 1179-1193; Worm, S.W., Sabin, C.A., Reiss, P., El-Sadr, W., Monforte, A.D., Pradier, C., Presence of the metabolic syndrome (MS) is not a better predictor of cardiovascular disease (CVD) than the sum of its components in HIV-infected individuals Data Collection on Adverse Events of Anti-HIV Drugs (The D:A:D study) (2009) Diabetes Care, 32, pp. 474-480; Wand, H., Calmy, A., Carey, D.L., Samaras, K., Carr Alaw, M.G., Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection (2007) AIDS, 21, pp. 2445-2453; Sabin, C.A., Weber, R., Fontas, E., Dabis, F., Wit, S.D., Worm, S.W., Underutilisation of recommended interventions for the prevention of coronary heart disease (CHD) in HIV-infected patients with established cardiovascular disease or diabetes mellitus: Results from a multicohort study (2007) 14th Conference on Retroviruses and Opportunistic Infections (CROI) Los Angeles, USA; Grundy, S.M., Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute (2005) Arterioscler Thromb Vasc Biol, 25, pp. 2243-2244; Gotto Jr., A.M., Blackburn, G.L., Dailey Ge, I.I.I., Garber, A.J., Grundy, S.M., Sobel, B.E., The metabolic syndrome: A call to action (2006) Coron Artery Dis, 17, pp. 77-80; Olijhoek, J.K., Van Der, G.Y., Haffner, S.M., Visseren, F.L., Defining the metabolic syndrome: Resolving unresolved issues? (2007) Eur J Intern Med, 18, pp. 309-313; Dube, M.P., Stein, J.H., Aberg, J.A., Fichtenbaum, C.J., Gerber, J.G., Tashima, K.T., Guidelines for the evaluation and management of dyslipidemiain human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group (2003) Clin Infect Dis, 37, pp. 613-627; Lundgren, J.D., Battegay, M., Behrens, G., De Ws Guaraldi, G., Katlama, C., European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV (2008) HIV Med, 9, pp. 72-81; Sattar, N., McConnachie, A., Shaper, A.G., Blauw, G.J., Buckley, B.M., De Craen, A.J., Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies (2008) Lancet, 371, pp. 1927-1935; Kahn, R., Buse, J., Ferrannini, E., Stern, M., The metabolic syndrome: Time for a critical appraisal - Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes (2005) Diabetes Care, 28 (9), pp. 2289-2304. , DOI 10.2337/diacare.28.9.2289",
year = "2010",
month = jan,
doi = "10.1097/QAD.0b013e328334344e",
language = "English",
volume = "24",
pages = "427--435",
number = "3",
}